Medically reviewed by Dr. Giovanni Scornavacca — Hair Restoration Specialist, Carisma Hair Clinic, St Julian's, Malta. 20+ years clinical experience, trained in Rome and Bologna.

Medically reviewed by Dr. Giovanni Scornavacca — Hair Restoration Specialist, Carisma Hair Clinic, St Julian's, Malta. 20+ years clinical experience.

How Long Does Finasteride Take to Work? A Realistic Timeline

How long does finasteride take to work? Finasteride typically begins reducing DHT levels within days of the first dose, but visible results follow a longer biological schedule. Most patients see hair loss stabilise between three and six months. Measurable regrowth, where it occurs, generally appears between six and twelve months. Twelve months is the appropriate clinical assessment point. Results may vary for each individual, depending on Norwood stage, follicle viability, and treatment consistency.

{width="1200" height="630"} Photo by Ketut Subiyanto. The bathroom mirror is where most patients first notice change — and where patience is most tested.

There is a particular kind of scrutiny that happens in front of a bathroom mirror when you are waiting for a medication to work. You look at the same hairline, the same crown, the same light angle — searching for evidence that something is changing. For men who have started finasteride, that period of waiting is often the hardest part of treatment. The biochemical effect is real and rapid. The visible effect is neither.

Understanding the full finasteride timeline — what is happening in each phase, what counts as a positive sign, and what a realistic expectation looks like — changes how patients experience treatment. It also changes whether they stay on it long enough to find out if it works.

This article sets out the evidence-based timeline for finasteride, addresses the most common reasons patients stop prematurely, and explains how clinical monitoring at each stage gives you objective data rather than mirror-based guesswork. If you are considering hair loss treatment in Malta, or have already started finasteride and want to know where you are in the process, this guide covers what the clinical evidence actually shows.

Contents

• ›What Is Happening in the First Month
• ›Months Three to Six: Stabilisation
• ›Months Six to Twelve: Regrowth in Responsive Patients
• ›Month Twelve: The Proper Clinical Assessment Point
• ›Why Most People Quit Too Early
• ›Finasteride and Minoxidil Combined
• ›Malta Context: Norwood Stage and Follicle Viability
• ›Clinical Monitoring at Carisma Hair Clinic
• ›Frequently Asked Questions About Finasteride Timeline in Malta

What Is Happening in the First Month: The Biochemistry Begins Immediately

Finasteride's primary mechanism is the inhibition of type II 5-alpha reductase, the enzyme responsible for converting testosterone into dihydrotestosterone (DHT). DHT is the androgen that, in genetically susceptible men, binds to hair follicle receptors and progressively miniaturises them over time.

Within hours of the first dose, finasteride begins blocking this conversion. The landmark randomised controlled trial published in the Journal of the American Academy of Dermatology found that the 1 mg oral dose reduced serum DHT by approximately 71% and scalp DHT by approximately 64% [Kaufman KD et al., JAAD finasteride RCT]. This is not a gradual effect — DHT suppression begins with the first tablet and reaches its sustained level within a few weeks of daily dosing.

What this means in practice: the biological driver of your hair loss is being significantly interrupted from day one. The follicles are no longer receiving the sustained DHT signal that was shortening their growth cycles and causing progressive miniaturisation. The problem is that the hair follicle cycle does not respond to biochemistry on a daily schedule.

Each hair follicle operates on its own cycle of anagen (active growth), catagen (transition), and telogen (resting and shedding). A single cycle lasts approximately two to six years for scalp hair. When DHT levels fall, follicles that were in a damaged or shortened anagen phase do not immediately restart growth. They continue through their current phase. The body needs multiple cycles to begin demonstrating improved follicle behaviour — and those cycles take months.

During the first four to eight weeks, some men notice increased shedding. This is a recognised phenomenon: as follicles are pushed from a disrupted cycle into a normalised anagen phase, hairs in the resting phase are shed to make way. It is not evidence that finasteride is failing. If you are concerned about what to expect during treatment, including the shedding phase some patients experience, understanding its mechanism is reassuring — it indicates biological activity, not regression.

What to expect in month 1: No visible changes to density. DHT suppression is underway. Mild increased shedding may occur. This is normal.

Months Three to Six: Stabilisation — The First Meaningful Signal

The three-to-six month window is when most patients begin to see the first clinically relevant sign that finasteride is working. That sign is not regrowth. It is the slowing, and in many patients the cessation, of progressive hair loss.

Stabilisation is a meaningful outcome. Male pattern hair loss is, by definition, a progressive process. If you were losing ground every three months before treatment and you are no longer losing ground at month four, that is the medication doing what it was designed to do. A systematic review of finasteride clinical data confirms that approximately 83% of finasteride-treated men showed no further hair loss at the vertex (crown) at two years, compared with continued progression in the placebo group [Mella JM et al., PMC finasteride systematic review].

This stabilisation period is also when many patients make the mistake of concluding the medication is not working. They expected visible new growth. What they observe instead is that things look roughly the same as when they started. For someone who had been watching progressive decline, "the same" can feel like failure. Clinically, it represents the medication performing exactly as intended.

The difficulty at this stage is that without baseline documentation, it is genuinely hard to assess stabilisation. If you did not take standardised photographs at month zero, comparing month four to month zero is difficult. This is one reason that objective baseline measurement — whether through standardised photography or scalp imaging — is valuable at the start of any treatment course. It replaces subjective perception with documentable data.

{width="940" height="650" loading="lazy"} Photo by RDNE Stock project. Tracking your finasteride timeline against a calendar helps set realistic expectations for each phase.

What to expect months 3-6: Hair loss rate slows or stops. This is the primary efficacy signal in this window. You are unlikely to see cosmetically visible new growth yet, but you should not be losing further ground.

Months Six to Twelve: Regrowth in Responsive Patients

If stabilisation is the floor of finasteride's benefit, regrowth is the ceiling — and it occurs in a meaningful proportion of patients who remain on treatment through twelve months.

Clinical evidence indicates that approximately 61-66% of men who continued finasteride 1 mg through two years saw visible regrowth at the vertex (crown). This regrowth is more pronounced at the crown than at the frontal hairline, where approximately 37% of men in the same studies showed improvement at twelve months. These figures are from the vertex-centred clinical trials that formed the basis for regulatory approval; they reflect the evidence grade available.

Regrowth typically manifests first as fine, initially unpigmented vellus hairs in areas of thinning. Over weeks to months, these hairs gradually thicken and pigment as the follicle resumes normal anagen function. This process is slow enough that it is almost invisible week to week — which is another reason why photographic documentation and scalp imaging at structured time points is more informative than daily mirror observation.

The distinction between vertex and frontal response has a practical implication: men with primarily crown thinning tend to see stronger responses than those whose primary concern is a receding hairline. Evidence suggests the frontal response is more modest, and expectations should be calibrated accordingly. Stage and location of loss at the time of starting treatment are relevant variables. Results vary by stage of hair loss — earlier intervention, when more follicles are still viable, generally produces stronger outcomes.

What to expect months 6-12: In responsive patients, fine vellus hairs begin to appear in thinning areas, gradually thickening over subsequent months. This is the window where regrowth becomes visible if it is going to occur.

Month Twelve: The Proper Clinical Assessment Point

Twelve months on a consistent daily dose is the appropriate point at which to make a meaningful clinical assessment of finasteride's effect. Not six months, and not three. Twelve months.

There are two reasons for this. First, the hair growth cycle means that the follicles most recently affected by DHT suppression may only now be completing a full cycle and demonstrating improved anagen behaviour. Second, regrowth that began at month six or seven may only be cosmetically appreciable by month ten or eleven.

A clinical assessment at twelve months should include a comparison of standardised photographs taken at baseline and again at the twelve-month mark, alongside scalp imaging data where available. Density measurements derived from scalp imaging — which quantify the number of hairs per square centimetre and the average hair shaft diameter — provide a more objective picture than photographic comparison alone.

What constitutes a positive outcome at twelve months? Maintained density (no further loss) is a minimum threshold. Measurable improvement in density metrics represents a stronger positive response. The absence of any change from baseline — given that hair loss in untreated men of similar age continues to progress — is itself a meaningful result.

Patients who have not seen any response at twelve months of consistent use, verified by objective measurement, warrant a clinical review. This may involve assessing treatment adherence, evaluating whether the diagnosis is correct (not all hair loss is androgenetic alopecia), or considering whether additional or alternative treatment approaches are appropriate. NHS hair loss guidance also reinforces that realistic expectations and consistent use are essential before assessing any medical hair treatment [NHS, Hair Loss guidance].

Why Most People Quit Too Early: The Six-Month Plateau Problem

The most common reason finasteride does not work for a given patient is that the patient stopped taking it before it had time to work.

This is not speculation — it is one of the most consistent findings in adherence research across all medical treatments, and it is particularly pronounced in hair loss treatment because the expected timeline is genuinely long, the early signals are subtle, and the absence of visible regrowth in month three is falsely interpreted as failure.

The pattern typically looks like this: a patient starts finasteride with an expectation of results within three months. At month three, they notice increased shedding or no visible improvement. They conclude it is not working. They stop. They never reach the phase — months six through twelve — where the medication may have demonstrated its actual effect.

The six-month plateau is a concept worth naming precisely: it is not that finasteride stops working at six months. It is that the patient stops waiting. The medication cannot demonstrate regrowth that takes twelve months to manifest if it is discontinued at six.

Adherence research in androgenetic alopecia consistently shows that persistence through twelve months is the variable most strongly correlated with patient-reported satisfaction. Patients who receive a structured timeline at the start of treatment, with explicit milestones to expect at each stage, show measurably better adherence than those who are simply told to take the tablet daily.

This is why the clinical structure of treatment matters as much as the prescription. Knowing that month one is biochemistry without visible change, that month four means looking for stabilisation rather than growth, and that month ten is when growth may become cosmetically appreciable — this information changes patient behaviour in ways that directly affect outcomes.

Finasteride and Minoxidil Combined: Does the Timeline Compress?

For patients who use finasteride in combination with topical minoxidil, clinical evidence suggests the timeline to both stabilisation and regrowth is typically shorter, and the magnitude of improvement is greater than either treatment produces alone.

Finasteride reduces DHT, interrupting the principal driver of follicle miniaturisation. Minoxidil operates through a distinct mechanism — it is a potassium channel opener that prolongs the anagen (active growth) phase and increases blood flow to the dermal papilla. The two mechanisms are complementary rather than redundant. A meta-analysis of randomised controlled trials confirmed that combination therapy produces significantly greater improvements in hair density, hair shaft diameter, and global photographic assessment than either monotherapy [Hu R et al., topical minoxidil systematic review].

In practice, patients on combination therapy often report stabilisation appearing somewhat earlier than the three-to-six month window, and first signs of regrowth appearing closer to month five or six rather than month eight or nine. These are clinical observations rather than precisely quantified trial data — but the directional evidence supports combination therapy as producing a more rapid meaningful response.

For patients who are within the viable treatment window — broadly, men in Norwood stages I through IV with miniaturised but not completely dormant follicles — comparing your full treatment options is worth addressing early, because beginning combination therapy at the outset may produce a more compelling twelve-month result than starting on monotherapy and adding a second agent later.

Malta Context: Norwood Stage and the Follicle Viability Window

One question that matters for setting realistic timeline expectations is: how much of the hair loss is recoverable?

Follicles that have been exposed to chronic DHT over many years progress from miniaturised (producing fine, thin hairs) to permanently dormant (producing no cosmetically meaningful hair at all). Finasteride may rescue and strengthen a miniaturised follicle. It cannot revive a dormant one.

This means that for men in the earlier Norwood stages — broadly stages I through III — the follicle population is still largely viable, the miniaturisation process is reversible, and the timeline for seeing meaningful regrowth is shorter because the follicles are still capable of responding. For men in stages IV through VI, the same medication may produce stabilisation of remaining hair but is less likely to generate cosmetically meaningful recovery in areas where follicle dormancy has progressed significantly.

In Malta, where general practitioner awareness of hair loss medicine is variable and specialist hair loss consultation is not universally accessed, men frequently seek evaluation at later stages than is clinically optimal. A man who noticed his hairline changing at 28 and is now 35 may have several additional years of DHT-driven miniaturisation that he did not need to accrue. Starting earlier — when more follicles are still in the viable miniaturised state rather than the dormant state — produces a longer runway of response and a better twelve-month outcome.

If you are in an early Norwood stage and considering starting treatment, the timeline above is generally applicable. If you are at a more advanced stage, the realistic outcome conversation shifts from "how much regrowth can I expect" to "how effectively can we preserve what remains." Both are valid treatment goals — but they are different conversations, and both deserve an honest clinical framing rather than generalised optimism.

Clinical Monitoring at Carisma Hair Clinic: Objective Data at Each Stage

At Carisma Hair Clinic, patients on the Hair Reset Protocol receive scalp imaging and density mapping at structured intervals — baseline, ninety days, and six months — using standardised scalp imaging technology that measures hair count per square centimetre and average hair shaft diameter.

This matters because it replaces mirror-based perception with quantifiable data. When a patient at month four asks whether finasteride is working, the answer should not be based on how the patient feels about their reflection on a given morning. It should be based on whether hair density has been maintained, and whether the progression metrics have changed compared to the documented baseline.

The ninety-day scan serves a specific function: it documents the stabilisation phase. If density at ninety days is equivalent to baseline, that is evidence of halted progression — not stasis, but active suppression of the loss trajectory. The six-month scan adds the first indication of whether any follicle recovery is beginning, expressed as a measurable increase in hair shaft diameter in the treatment zone.

Patients who can see objective numbers change — even modestly — show significantly better adherence through the full twelve-month assessment period. The data replaces doubt with evidence. That shift in the patient's relationship to treatment is clinically meaningful, not merely psychological.

Frequently Asked Questions About Finasteride Timeline in Malta

How long does finasteride take to stop hair loss?

Most patients see hair loss stabilise between three and six months of consistent daily use. Finasteride reduces DHT levels within days of the first dose, but the hair follicle cycle means visible stabilisation takes several months to appear. Some men notice earlier stabilisation; for others, the full effect requires the complete six-month window. The absence of further loss is the primary efficacy signal in this phase — it is a meaningful result even before any regrowth appears.

When will I see regrowth on finasteride?

Visible regrowth, where it occurs, typically becomes apparent between six and twelve months of treatment. Clinical evidence indicates that approximately 61-66% of men who continued finasteride through two years saw visible regrowth at the vertex (crown). Initial regrowth presents as fine, lightly pigmented vellus hairs that gradually thicken over subsequent months. Frontal hairline regrowth occurs in a smaller proportion of patients than vertex regrowth. Twelve months is the appropriate point to assess whether regrowth has occurred.

Why is my hair still falling out after 3 months on finasteride?

Three months is within the stabilisation window, not the regrowth window. Some continued shedding in the first four to eight weeks is a recognised and expected response — as finasteride restores a more normal follicle cycle, hairs in the resting phase are shed to make way for new growth. If shedding persists beyond three months at a rate significantly above your pre-treatment baseline, that warrants a clinical review. But some ongoing hair cycling — which includes shedding of older hairs — is normal even on effective treatment.

What happens if I stop taking finasteride before 12 months?

Hair loss typically resumes, and any gains are progressively reversed. Finasteride's effect is suppressive, not curative — it interrupts the DHT signal that drives miniaturisation while the medication is active. Stopping before twelve months means the medication has not had the full window to demonstrate its peak effect, and any early stabilisation may not be maintained. The hair loss trajectory generally returns toward its pre-treatment rate within six to twelve months of discontinuation. For patients considering stopping due to concerns about side effects, a conversation with the prescribing doctor — rather than unilateral discontinuation — is the appropriate first step.

Does finasteride work faster when combined with minoxidil?

The clinical evidence suggests yes. A meta-analysis of randomised controlled trials found that combination therapy (finasteride plus topical minoxidil) produces significantly greater improvements in hair density and global assessment than either treatment alone. Patients on combination therapy tend to see stabilisation somewhat earlier and first signs of regrowth closer to month five or six, compared with month eight to nine on finasteride monotherapy. The two medications work through distinct, complementary mechanisms, which is why combination produces additive rather than merely overlapping benefits.

How much does finasteride treatment cost in Malta?

The cost of finasteride in Malta varies depending on whether you access it through a private prescription or as part of a supervised hair loss programme. A clinical assessment — including scalp imaging, density mapping, and a personalised protocol — gives you a documented baseline and removes the guesswork from any treatment decision. At Carisma Hair Clinic, initial consultation is free. For an accurate breakdown of treatment costs based on your specific presentation, book a consultation.

Is finasteride safe for long-term use?

Finasteride 1 mg has been in continuous clinical use for male pattern hair loss since the late 1990s and has an established long-term safety profile. Side effects — including reduced libido and erectile changes — occur in approximately 1-2% of users in controlled trials and are typically reversible on discontinuation. Finasteride is not suitable for use by women who are pregnant or may become pregnant. As with any prescription medication, ongoing use should be supervised by a qualified healthcare professional.

Do I need a prescription for finasteride in Malta?

Yes. Finasteride is a prescription-only medication in Malta and across the EU. It cannot be legally dispensed without a valid prescription from a licensed doctor. Online sources offering finasteride without prescription do not meet EU regulatory standards and carry significant risks. The appropriate route is a clinical assessment with a qualified hair loss specialist who can evaluate whether finasteride is suitable for your specific pattern of loss. You can find out more about getting finasteride in Malta through our dedicated guide.

Ready to Take Control of Your Hair Loss?

If you have been researching your options and want a clinical assessment rather than another generic recommendation, Carisma Hair Clinic offers a comprehensive diagnostic consultation — scalp imaging, density mapping, and a personalised protocol designed around your specific pattern of loss.

→ Book Your Free Hair Loss Consultation

Dr. Giovanni Scornavacca and the team at Carisma Hair Clinic are available at our St Julian's clinic.

About the Author

Dr. Giovanni Scornavacca is a hair restoration specialist with over 20 years of clinical experience, with advanced training at universities in Rome and Bologna. He leads the Hair Reset Protocol at Carisma Hair Clinic — Malta's most complete non-surgical hair regrowth programme. Dr. Scornavacca specialises in diagnosing and treating androgenetic alopecia, telogen effluvium, and complex hair loss presentations using a combination of PRP, exosome therapy, and prescription protocols tailored to each patient.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Results may vary for each individual. Always consult a qualified healthcare professional before starting any hair loss treatment. Finasteride is a prescription-only medication and must not be used or handled by women who are pregnant or may become pregnant. Dr. Giovanni Scornavacca and Carisma Hair Clinic are available for clinical consultation at our St Julian's, Malta clinic.

Written and reviewed by Dr. Giovanni Scornavacca, Carisma Hair Clinic. Published: 26 June 2026.

Ready to Take Action?

Book a free consultation with Dr. Giovanni Scornavacca to get a personalised hair loss assessment and treatment plan.